Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Urinary Bladder Neoplasms × Dutasteride × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 31 Prostatic Hyperplasia 5 Neoplasms 4 Urinary Bladder Neoplasms 1 Recurrence 1 Neoplasm Metastasis 1 Multiple Endocrine Neoplasia Type 1 1 Lower Urinary Tract Symptoms 1 Erectile Dysfunction 1 Adenocarcinoma of the Prostate 1

Interventions

Gemcitabine 154 Cisplatin 115 pembrolizumab 80 Cystectomy 45 Nivolumab 42 Carboplatin 42 Paclitaxel 41 Mitomycin 39 Docetaxel 39 atezolizumab 33 Magnetic Resonance Spectroscopy 32 Radiotherapy 31 durvalumab 30 avelumab 26 BCG Vaccine 26 Specimen Handling 25 Doxorubicin 23 Cystoscopy 23 enfortumab vedotin 22 Fluorouracil 18 Methotrexate 17 Vinblastine 16 Standard of Care 15 Ipilimumab 14 Filgrastim 14 5-aminolevulinic acid hexyl ester 14 Surgical Procedures, Operative 13 Sunitinib 13 Biopsy 13 vinflunine 12

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT07420517 2026-03-30

DutaBCa-1

CHU de Quebec-Universite Laval

Phase 2 Recruiting

Urinary Bladder Neoplasms, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon ⚡